TNF Inhibitor denied for failing step therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for tnf inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Uses Step Therapy for TNF Inhibitors

Step therapy — sometimes called "fail-first" — requires that you try one or more less expensive or lower-risk medications before a plan will approve a more costly option like a TNF inhibitor. Blue Cross Blue Shield's step-therapy protocol for biologics typically requires documented use of conventional disease-modifying therapies (such as methotrexate, sulfasalazine, or similar agents, depending on your condition) and sometimes a first-line biologic before approving the requested TNF inhibitor. A step-therapy denial means BCBS believes the required prior steps have not been adequately documented or completed.

## Why This Denial Is Appealable

Step-therapy denials are frequently overturned when one of these conditions is met: (a) you have already tried and failed the required prior-step medications; (b) a required prior medication is contraindicated or clinically inappropriate for you; or (c) you have been stable on the requested TNF inhibitor and a step-back would pose clinical risk. Most states now have step-therapy override laws requiring insurers to grant exceptions in these circumstances. Confirm whether your state's law applies to your plan type.

## Federal Appeal Rights

• Internal appeal: File under ERISA §503 (employer plans) or your state's insurance code. Request a step-therapy exception simultaneously if your state law provides one.
• External review (ACA §2719): Available after exhausting internal appeals, generally within four months of the final internal denial.
• Expedited review: If your condition is active and step-back poses a risk of serious harm, request expedited review. Decisions are typically required within 72 hours.
• State step-therapy override: Many states require insurers to grant an override when prior steps have failed or are contraindicated. Look up your state's step-therapy law and cite it in your appeal.

## Documentation to Gather

1. Prior-therapy history: A complete, dated record of every step-therapy drug you have tried: drug name, start date, discontinuation date, dose adjustments, and the specific reason for stopping (inadequate response, adverse effect, intolerance, contraindication). 2. Clinical outcome records: Lab results, physician assessments, or imaging that objectively document the failure or inadequacy of prior treatments. 3. Contraindication documentation: If a required step-therapy drug is inappropriate for you due to a comorbidity, drug interaction, or prior adverse event, your prescriber must document this clearly in the chart and in the appeal letter. 4. Prescriber medical-necessity letter: Addresses each required step, explains why the TNF inhibitor is now the appropriate next treatment, and references the applicable specialty-society guideline (ACR, AAD, AGA, etc.). 5. BCBS step-therapy protocol: Obtain the exact step-therapy criteria for your drug and diagnosis so you can confirm which steps are required and which you have completed.

## Criteria-Mapping Structure

| Required Step-Therapy Drug | Tried? | Dates | Outcome / Reason Not Appropriate | |---|---|---|---| | [Step 1 per policy] | Yes/No | [Dates] | [Response or clinical reason] | | [Step 2 per policy] | Yes/No | | |

Document every required step explicitly. A prescriber letter that walks through each policy requirement and matches it to a chart fact — rather than a general statement of medical necessity — is the single most effective tool for overturning a step-therapy denial.